Abstract 76P
Background
The study is aimed to identify perception and satisfaction of cancer patients who participate in clinical trials.
Methods
The participants of the study were 110 cancer patients who participated in clinical trials over 2nd cycle at a tertiary hospital, Seoul, South Korea. The instruments used were the perception and satisfaction of cancer patients in clinical trials developed after evaluating content validity index. The collected data were analyzed with descriptive statistics, independent t-test, one-way ANOVA and Pearson Correlation Coefficients.
Results
The mean perception of clinical trial of patients was 3.97±0.46 out of 5.0. The mean satisfaction of clinical trial of patients was 4.10±0.55 out of 5.0. The perception of cancer patients in clinical trials was significantly difference according to types of cancers (F = 2.88, p=.018), participation period (F = 3.13, p=.029) and subjective understanding of the clinical trial (t = 2.65, p=.015). Satisfaction of cancer patients showed significant difference according to religion (t = 2.32, p=.023), participation period (F = 3.39, p=.021), motive to participate (F = 3.18, p=.010) and decision maker of participation (t = 2.60, p =.025). Perception and satisfaction of cancer patients in clinical trials were positively correlated (r=.66, p<.001).
Conclusions
The results of study can be used as a basis for education program for cancer patients participating in clinical trials.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
314P - An EGF motif of Del1 inhibits efficient angiogenesis and suppresses tumour growth in vivo
Presenter: Hisataka Kitano
Session: Poster display session
Resources:
Abstract
315P - Inhibition of JAK1 sensitizes human head and neck cancer cells to cetuximab
Presenter: James Bonner
Session: Poster display session
Resources:
Abstract
316TiP - Neoadjuvant and adjuvant pembrolizumab (pembro) plus standard of care (SOC) in patients (pts) with resectable locally advanced (LA) head and neck squamous cell carcinoma (HNSCC): The phase III KEYNOTE-689 study
Presenter: Ezra Cohen
Session: Poster display session
Resources:
Abstract
322P - Three-year overall survival update from the PACIFIC trial
Presenter: Yi-Long Wu
Session: Poster display session
Resources:
Abstract
323P - Novel tumour mutation score versus tumour mutation burden in predicting survival after immunotherapy in pan-cancer from MSK-IMPACT cohort
Presenter: Yuan Li
Session: Poster display session
Resources:
Abstract
324P - A novel anti-PD-1 antibody HLX10 study led to the initiation of combination immunotherapy
Presenter: Tsu Yi Chao
Session: Poster display session
Resources:
Abstract
325P - Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma
Presenter: Lawrence Wong
Session: Poster display session
Resources:
Abstract
326P - Autologous V gamma 9 V delta 2 T cell therapy to target Epstein Barr Virus (EBV)-related malignancies
Presenter: Esdy Rozali
Session: Poster display session
Resources:
Abstract
327P - Neoantigen profile of hepatocellular carcinoma reveals its correlation with tumour progression and clonal evolution
Presenter: Xiaolong Liu
Session: Poster display session
Resources:
Abstract
328P - A retrospective analysis of patients with non-small cell lung cancer who developed drug-induced lung disorder by immune checkpoint inhibitors
Presenter: Fumiko Hayashi
Session: Poster display session
Resources:
Abstract